P1283: CIRCULATING IMMUNE CELLS IN CLASSICAL HODGKIN LYMPHOMA IN RELATION TO TUMOR BURDEN AND TREATMENT

P1283: CIRCULATING IMMUNE CELLS IN CLASSICAL HODGKIN LYMPHOMA IN RELATION TO TUMOR BURDEN AND TREATMENT

Bibliographic Details
Main Authors:	T. A. Mulder, M. L. Andersson, K. Heimersson, I. Xagoraris, B. E. Wahlin, G. Rassidakis, L. Hansson, M. Palma
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000847996.60643.8d

Similar Items

P032: Circulating immune biomarkers in classical Hodgkin lymphoma in relation to tumor burden and response to treatment.
by: Tom A. Mulder, et al.
Published: (2022-10-01)

Immune Biomarkers in the Peripheral Blood and Tumor Microenvironment of Classical Hodgkin Lymphoma Patients in Relation to Tumor Burden and Response to Treatment
by: Tom A. Mulder, et al.
Published: (2022-11-01)

P053: The cGAS-STING anti-tumor immune response pathway as a potential therapeutic target in classical Hodgkin Lymphoma (cHL)
by: Ioanna Xagoraris, et al.
Published: (2022-10-01)

P052: Targeting CSN5/JAB1 oncogene in classical Hodgkin Lymphoma (cHL)
by: Ioanna Xagoraris, et al.
Published: (2022-10-01)

Circulating tumor DNA for monitoring classic Hodgkin lymphoma patients: Correlation with FDG‐PET/CT
by: Sara Fernández, et al.
Published: (2024-02-01)

P1304: THE NOVEL TUMOR SUPPRESSOR SAMHD1 CONTRIBUTES TO ANTI-TUMOR RESPONSES IN A CGAS-STING-DEPENDENT OR INDEPENDENT PATHWAY IN HODGKIN LYMPHOMA (HL)
by: I. Xagoraris, et al.
Published: (2022-06-01)

Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study
by: Vincent Camus, et al.
Published: (2020-02-01)

Bringing circulating tumor DNA to the clinic in Hodgkin lymphoma
by: David M. Kurtz
Published: (2021-01-01)

T009 (0083) CIRCULATING TUMOR DNA AS A BIOMARKER FOR THE NONINVASIVE GENOTYPING AND MONITORING OF CLASSICAL HODGKIN LYMPHOMA
Published: (2018-10-01)

Genetics of classical Hodgkin Lymphoma
by: Gianluca Schiavoni, et al.
Published: (2018-06-01)

S225: CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER AT BASELINE AND IMPROVES THE ACCURACY OF INTERIM PET IN CLASSIC HODGKIN LYMPHOMA
by: M. C. Pirosa, et al.
Published: (2022-06-01)

Composite follicular lymphoma and classic Hodgkin lymphoma
by: Han-Na Kim, et al.
Published: (2022-01-01)

The recognition and enforcement of debts under the statutes of Acton Burnell (1283) and Merchants (1285), 1283-1307
by: McNall, C
Published: (2000)

Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab
by: Yuankai Shi, et al.
Published: (2020-04-01)

Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin’s lymphoma
by: Beatriz Sánchez-Espiridión, et al.
Published: (2012-07-01)

Real‐world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000–2014, focusing on patients aged >60 years
by: Björn Engelbrekt Wahlin, et al.
Published: (2021-08-01)

The real risk of secondary non-Hodgkin lymphoma following classical Hodgkin lymphoma
by: Ahmet Dogan
Published: (2022-10-01)

Controversies in the Treatment of Classical Hodgkin Lymphoma
by: Dennis A. Eichenauer, et al.
Published: (2018-10-01)

Classical Hodgkin’s Lymphoma Presenting as Erythroderma
by: Kumar Parimalam, et al.
Published: (2022-11-01)

ALK Negative Inflammatory Myofibroblastic Tumor Synchronous with Classical Hodgkin Lymphoma
by: Letícia Sandoval, et al.
Published: (2019-01-01)

Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma
by: Jodi Chiu, et al.
Published: (2018-02-01)

Identification of a novel monocytic phenotype in Classic Hodgkin Lymphoma tumor microenvironment.
by: Ginell R Post, et al.
Published: (2019-01-01)

Conditional Survival and Annual Hazard Estimates of Classical Hodgkin Lymphoma
by: Nuersulitan R, et al.
Published: (2021-08-01)

Complete Resolution of Tumor Burden of Primary Cardiac Non-Hodgkin’s Lymphoma
by: Rina Mauricio, et al.
Published: (2016-01-01)

Hemophagocytic Lymphohistiocytosis in a Patient with Classical Hodgkin Lymphoma
by: G. Hyun, et al.
Published: (2016-01-01)

Tumor-Infiltrating Macrophages in Post-Transplant, Relapsed Classical Hodgkin Lymphoma Are Donor-Derived.
by: Genevieve M Crane, et al.
Published: (2016-01-01)

Evolution of drug therapy for classical Hodgkin lymphoma
by: N. Y. Samaneva, et al.
Published: (2022-09-01)

CAR-T Cell Therapy for Classical Hodgkin Lymphoma
by: Mikalai Katsin, et al.
Published: (2023-12-01)

Current directions in the treatment of classical Hodgkin lymphoma
by: Frank G. Keller, et al.
Published: (2023-11-01)

Treatment Of Classical Hodgkin Lymphoma: The State Of The Art
by: Carmino Antonio de Souza, et al.
Published: (2023-10-01)

Bone marrow involvement by classic Hodgkin lymphoma
by: Mohammad Barouqa, et al.
Published: (2022-05-01)

Aberrant synaptophysin expression in classic Hodgkin lymphoma
by: Soyoung Im, et al.
Published: (2022-11-01)

Bob-1 is expressed in classic Hodgkin lymphoma
by: Abd El All Howayda S
Published: (2007-03-01)

Relapsed and refractory classical Hodgkin lymphoma immunotherapy
by: Kirill Lepik
Published: (2020-10-01)

Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma
by: Vincent Camus, et al.
Published: (2016-09-01)

The Tumor Suppressive mir-148a Is Epigenetically Inactivated in Classical Hodgkin Lymphoma
by: Julia Paczkowska, et al.
Published: (2020-10-01)

Bone marrow composition features and possibilities of tumor involvement diagnosing in patients with classic Hodgkin’s lymphoma
by: F. M. Abbasbeyli, et al.
Published: (2023-09-01)

Immune targeting of the microenvironment in classical Hodgkin’s lymphoma: insights for the hematologist
by: Nicole A. Carreau, et al.
Published: (2019-05-01)

Immune and stromal transcriptional patterns that influence the outcome of classic Hodgkin lymphoma
by: Victoria Menéndez, et al.
Published: (2024-01-01)

MASSIVE TUMOR BURDEN IN HODGKIN’S LYMPHOMA AS A PROGNOSTIC FACTOR IN YOUNG ADULTS
by: A. P. Karitsky
Published: (2016-02-01)